Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer
暂无分享,去创建一个
[1] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Saeed Sadeghi,et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[5] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[6] S. Johnston,et al. Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance. , 2005, Endocrine-related cancer.
[7] J. Ragaz,et al. Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] David Cameron,et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.
[9] Robert J. Mayer,et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.
[10] D. Machin,et al. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. , 1997, Journal of the National Cancer Institute.
[11] H. Gómez,et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Lena,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial , 2007 .
[13] S. Shak,et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients , 2006, Breast Cancer Research.
[14] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[15] D. Hayes,et al. Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection , 2007 .
[16] Roman Rouzier,et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Jack Cuzick,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.
[18] D. Hayes,et al. Extended follow-up results from a prospective multi-center study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection, satisfaction, and anxiety. , 2009 .
[19] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[20] W. Loo,et al. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. , 2008, Cancer letters.
[21] K. Blackwell,et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. , 2009, The Lancet. Oncology.
[22] M. Ahmed,et al. Breast cancer: role of neoadjuvant therapy. , 2009, International journal of surgery.
[23] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[24] W. Loo,et al. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer , 2008, The Journal of Steroid Biochemistry and Molecular Biology.
[25] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[26] E. Winer,et al. How well do standard prognostic criteria predict oncotype DX (ODX) scores , 2007 .
[27] R. Venkatraman. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials , 2008 .